metformin has been researched along with Lung Diseases, Interstitial in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a well-established and widely prescribed oral hypoglycemic drug, and has gained attention for its potential anticancer effects." | 5.42 | Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. ( Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K, 2015) |
| "Metformin is a well-established and widely prescribed oral hypoglycemic drug, and has gained attention for its potential anticancer effects." | 1.42 | Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. ( Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kinoshita, S | 1 |
| Hosomi, K | 1 |
| Yokoyama, S | 1 |
| Takada, M | 1 |
| Okada, J | 1 |
| Yamada, E | 1 |
| Niijima, Y | 1 |
| Okada, S | 1 |
| Yamada, M | 1 |
| Zuccarini, G | 1 |
| Bocchino, M | 1 |
| Assante, LR | 1 |
| Rea, G | 1 |
| Sanduzzi, A | 1 |
| Li, L | 1 |
| Huang, W | 1 |
| Li, K | 1 |
| Zhang, K | 1 |
| Lin, C | 1 |
| Han, R | 1 |
| Lu, C | 1 |
| Wang, Y | 1 |
| Chen, H | 1 |
| Sun, F | 1 |
| He, Y | 1 |
4 other studies available for metformin and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Humans; Hyperthyroidism; Hypoglycemic Agents; L | 2020 |
Metformin administration attenuates dipeptidyl peptidase-4 inhibitor-induced increases in Krebs von den Lungen-6 (KL-6) levels.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation; Humans; H | 2019 |
Metformin/glibenclamide-related interstitial lung disease: a case report.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; | 2014 |
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flo | 2015 |